HRT Financial’s Avid Bioservices, Inc. Common Stock CDMO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
Sell
-27,844
Closed -$343K 3611
2024
Q4
$343K Sell
27,844
-149,790
-84% -$1.72M ﹤0.01% 1642
2024
Q3
$2.02M Buy
177,634
+50,933
+40% +$511K 0.01% 877
2024
Q2
$904K Buy
+126,701
New +$969K 0.01% 1060
2024
Q1
Sell
-442,423
Closed -$2.88M 3258
2023
Q4
$2.88M Buy
442,423
+404,260
+1,059% +$2.61M 0.02% 503
2023
Q3
$360K Buy
+38,163
New +$459K ﹤0.01% 1577
2023
Q2
Sell
-79,942
Closed -$1.5M 3455
2023
Q1
$1.5M Buy
+79,942
New +$1.31M 0.02% 740
2022
Q3
Sell
-52,322
Closed -$798K 3651
2022
Q2
$798K Buy
52,322
+39,139
+297% +$579K 0.01% 1090
2022
Q1
$268K Sell
13,183
-8,733
-40% -$178K ﹤0.01% 2312
2021
Q4
$639K Buy
+21,916
New +$627K ﹤0.01% 1574
2021
Q1
Sell
-33,608
Closed -$387K 3252
2020
Q4
$387K Buy
+33,608
New +$307K 0.01% 1154
2019
Q4
Sell
-12,878
Closed -$68K 1750
2019
Q3
$68K Buy
+12,878
New +$79.9K ﹤0.01% 1282

Other funds holding CDMO

HRT Financial's CDMO Position: Q1 2025 in Review

HRT Financial sold out of Avid Bioservices, Inc. Common Stock (CDMO) in Q1 2025, closing a stake of 27,844 shares — an estimated $343K sold.

HRT Financial first reported a position in CDMO in Q3 2019 and held it in 11 quarters. The position peaked at $2.88M in Q4 2023. 2 funds tracked by Wall St. Rank hold CDMO as of Q1 2025.

  • HRT Financial reported no remaining Avid Bioservices, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
  • HRT Financial sold 27,844 Avid Bioservices, Inc. Common Stock shares in Q1 2025, an estimated $343K.
  • HRT Financial first reported a position in Avid Bioservices, Inc. Common Stock in Q3 2019 and held it in 11 quarters.
  • HRT Financial's Avid Bioservices, Inc. Common Stock position peaked at $2.88M in Q4 2023.
  • 2 funds tracked by Wall St. Rank held Avid Bioservices, Inc. Common Stock as of Q1 2025.

Based on HRT Financial's 13F filing for Q1 2025, filed 15 May 2025.